Replies to post #122789 on Biotech Values

[DewDiligence]

…several PBMs are listing Pradaxa in the "non-covered" category for atrial fibrillation presently.

That’s surprising insofar as it’s been nine months since Pradaxa received FDA approval. Perhaps B-I’s marketing operation in the US leaves something to be desired.

A related question is why B-I has not made an effort to get Pradaxa approved in the US for the hip/knee indication despite Pradaxa’s European approval for this indication way back in 2008.

…a possible administrative nightmare and one filled with physician and patient dissatisfaction if the PBMs were to selectively allow any of these drugs for one FDA indication, yet not for another present, or future, FDA indication.

I’m glad this is not my problem :- )